# OnCo record irae-hypophysitis-adrenal (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/irae-hypophysitis-adrenal/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "irae-hypophysitis-adrenal" ;
  schema:name "Checkpoint inhibitor hypophysitis and adrenal insufficiency: emergency treatment, replacement and steroid emergency card"@en ;
  schema:alternateName "immune checkpoint inhibitor hypophysitis"@en, "ICI adrenal insufficiency"@en, "adrenal crisis on immunotherapy"@en, "cortisol deficiency immunotherapy"@en, "steroid sick day rules immunotherapy"@en, "ipilimumab hypophysitis"@en ;
  schema:description "Immunotherapy can damage the pituitary or adrenal glands so the body stops making cortisol, a hormone needed to survive illness. Anyone on immunotherapy who becomes very unwell should be treated for low cortisol at once while tests are done. Most then need hydrocortisone tablets for life, a steroid emergency card, and to know how to double the dose when ill. Immunotherapy can usually carry on."@en ;
  schema:url <https://onco.cc/protocols/irae-hypophysitis-adrenal/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "irae", "acute-oncology", "endocrine" ;
  onco:related <https://onco.cc/protocols/irae-colitis/>, <https://onco.cc/protocols/irae-pneumonitis/>, <https://onco.cc/protocols/hyponatraemia-siadh/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/hydrocortisone/> ;
  onco:institutions <https://onco.cc/institutions/sitc/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/immune-endocrinopathy/>, <https://onco.cc/terms/irae/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/> .
